Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2012, Article ID 167653, 4 pages
http://dx.doi.org/10.1155/2012/167653
Case Report

Myelodysplastic Syndrome with t(1;7) Associated with Marked Dysmegakarypoiesis & Severe Thrombocytopenia: A Case Report and Review of the Literature

Department of Diagnostic Haematology, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia

Received 29 December 2011; Accepted 1 February 2012

Academic Editors: E. Arellano-Rodrigo and R. Tiu

Copyright © 2012 Michael Gilbertson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. D. Brunning, J. M. Bennett, E. S. Matutes, A. Orazi, J. W. Vardiman, and J. Thiele, “Refractory cytopenia with multilineage dysplasia,” World Health Organisation, 98, 2008.
  2. J. L. Huret, “t(1;7)(q10;p10). Atlas of Genetics and Cytogenetics in Oncology and Haematology,” 2010, http://atlasgeneticsoncology.org/Genes/ETV6ID38.html.
  3. S. Horiike, M. Taniwaki, S. Misawa et al., “The unbalanced 1;7 translocation in de novo myelodysplastic syndrome and its clinical implication,” Cancer, vol. 65, no. 6, pp. 1350–1354, 1990. View at Google Scholar · View at Scopus
  4. M. Sanada, N. Uike, K. Ohyashiki et al., “Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms,” Leukemia, vol. 21, no. 5, pp. 992–997, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. L. Slovak, M. O'Donnell, D. D. Smith, and K. Gaal, “Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS,” Cancer Genetics and Cytogenetics, vol. 193, no. 2, pp. 78–85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Cruz-Bautista, I. Lerman, B. Perez-Enriquez et al., “Diagnostic challenge of glucagonoma: case report and literature review,” Endocrine Practice, vol. 12, no. 4, pp. 422–426, 2006. View at Google Scholar · View at Scopus
  7. M. A. Muros, M. Varsavsky, P. Iglesias Rozas et al., “Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues,” Clinical and Translational Oncology, vol. 11, no. 1, pp. 48–53, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. J. King, R. Quinn, D. M. Glenn et al., “Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases,” Cancer, vol. 113, no. 5, pp. 921–929, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Van Essen, E. P. Krenning, M. De Jong, R. Valkema, and D. J. Kwekkeboom, “Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours,” Acta Oncologica, vol. 46, no. 6, pp. 723–734, 2007. View at Publisher · View at Google Scholar · View at Scopus